FLT3 and acute myeloid leukemia: Beyond this secondary on-target mutation, AML cells can evade FLT3 inhibition through compensatory activation of alternative pathways (e.g., JAK/STAT, PI3K/AKT, MAPK), particularly in cases with co-occurring JAK mutations [103].